Washington as an Antibody Hub

Wednesday, April 10, 2013 (7:30 AM - 12:15 PM)

Topic Description: 

Join us for a topical event developed by Steve Gillis with an expert panel that will emphasize why everyone from industry leaders to legislators should be interested in the discussion of Washington’s status in the race for building a biotech/biomedical hub.  The greater Seattle area and surrounding region is host to a rich variety of biotech companies, ranging from early stage technologies to fully integrated commercial enterprises.  Washington has much to celebrate as we look back on past success, but how will we be focusing on future growth in this key technology area?  This conference will feature the key leaders driving the successful development in this specialized area as they cover the cutting-edge of new technologies and provide updates on recent clinical progress of new therapeutics.

Our Distinguished Speakers:

  • Jonathan Drachman, MD, Senior Vice President, Research and Translational Medicine, Seattle Genetics
  • Teri Foy, PhD, Chief Scientific Officer, VLST
  • Steve Gillis, PhD, Managing Director, ARCH Venture Partners
  • Ken Grabstein, PhD, Chief Scientific Officer, Allozyne Inc.
  • Pat Gray, PhD, Scientific Fellow, Omeros 
  • Jane Gross, PhD, Vice President, Research & Development, Emergent BioSolutions 
  • Rob Hershberg, MD, PhD, Founder, Chief Executive Officer, VentiRx Pharmaceuticals, Inc. 
  • Ken Mohler, Chief Scientific Officer, ZetaRx Biosciences, Inc.
  • Leni Ramos, MD, Chief Medical Officer, Theraclone Sciences
  • Randy Schatzman, PhD, Founder & Chief Executive Officer, Alder Biopharmaceuticals
  • Clay Siegall, PhD, Chairman & Chief Executive Officer, Seattle Genetics
  • Kristine Swiderek, PhD, Chief Scientific Officer, Theraclone Sciences
  • Sarah Warren, PhD, Director of Research, Oncofactor Corporation


What You’ll Learn:

  • How have Washington state biotechnology companies developed and implemented strategies to evolve into successful corporations?
  • What is the next step for Washington biotech companies?  How do they envision expanding beyond their current infrastructure and focus?
  • What company characteristics and milestones are necessary for investment at each phase of biotechnology development (preclinical, early clinical, late clinical and commercial)?
  • What are the new technologies that will be used to produce the next generation of antibody-based therapeutics?
  • Progress on antibody therapeutics in clinical trials

Who Should Attend?

  • Company CEO’s, Presidents, VP’s, and Business Development Officers
  • Academics
  • Investors 


Time:
  

7:30-8:00 am – Registration and Pre-Function
8:00 am – Program begins

Price:

Members: $60 | Future members: $75  | Students and 501c3 Non-Profit Organizations: $25

Thank you to our Pinnacle Sponsor:




Thank you to our Innovation Sponsors:


 
             
   


                
 

       
            



  









© 2012 Washington Biotechnology & Biomedical Association

        
Powered by YourMembership.com